Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carasent AB (publ)APXZF 73 12-1 Month Momentum % is N/A% as of Aug. 19, 2026. GuruFocus rates APXZF with a GF Score™ of 73/100 and a GF Value™ of $0.16. The stock has 5 warning signs investors should review. Among 660 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 50.3% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-19), Carasent AB (publ)'s 12-1 Month Momentum % is N/A%.
The industry rank for Carasent AB (publ)'s 12-1 Month Momentum % or its related term are showing as below:
APXZF's 12-1 Month Momentum % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: -14.57 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Carasent AB (publ) (OTCPK:APXZF) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Carasent AB (publ) 12-1 Month Momentum % Related Terms
APXZF vs VEEV, BTSG, HQY: 12-1 Month Momentum % Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) 12-1 Month Momentum % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s 12-1 Month Momentum % falls into.
Carasent AB (publ) (OTCPK:APXZF) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) (APXZF) has a 12-1 Month Momentum % of N/A% as of Aug. 19, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Carasent AB (publ) and its competitors. According to the industry distribution chart, Carasent AB (publ) ranks #328 out of 660 companies in the Healthcare Providers & Services industry, placing it in the top 49.7%.
Is Carasent AB (publ)'s 12-1 Month Momentum % too high?
Carasent AB (publ)'s current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Carasent AB (publ) ranks #328 out of 660 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Carasent AB (publ) has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s 12-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #328 out of 660 companies for 12-1 Month Momentum %. This puts Carasent AB (publ) in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Healthcare Providers & Services company?
A good 12-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Carasent AB (publ) and its competitors. Carasent AB (publ)'s current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current 12-1 Month Momentum % of N/A%. The stock's GF Value™ is $0.16, compared to a current price of $0.15 — trading 6.3% below its estimated fair value. The current 12-1 Month Momentum % is N/A%. Carasent AB (publ)'s overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current 12-1 Month Momentum % is N/A% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 6.3% below its estimated GF Value™ of $0.16.
Key valuation signals for APXZF:
12-1 Month Momentum %: N/A%
GF Value™: $0.16 vs. price of $0.15 (6.3% below fair value)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
73GF Score
Get the complete analysis for APXZF
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
